Premium
Preliminary Report of Clinical Outcomes After Single Crossover Bioresorbable Scaffold Implantation Without Routine Side Branch Strut Dilation
Author(s) -
Tanaka Akihito,
Jabbour Richard J.,
Kawamoto Hiroyoshi,
Mangieri Antonio,
Pagnesi Matteo,
Montalto Claudio,
Chieffo Alaide,
Carlino Mauro,
Montorfano Matteo,
Latib Azeem,
Colombo Antonio
Publication year - 2016
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26586
Subject(s) - medicine , ostium , myocardial infarction , bioresorbable scaffold , dilation (metric space) , cardiology , timi , lesion , revascularization , thrombosis , radiology , surgery , percutaneous coronary intervention , mathematics , combinatorics
Objectives The objective of this study was to investigate clinical outcomes following single crossover bioresorbable scaffold (BRS) implantation without routine side branch (SB) strut dilation. Background It is unknown whether SB strut dilation is routinely required after single crossover BRS implantation if there is no compromise of the jailed SB. Methods Among 187 bifurcation lesions treated with Absorb BRS, 115 lesions (101 patients) were treated with single crossover BRS implantation. Strut dilation toward SB was considered only when SB was compromised (SB TIMI flow < 3 or SB ostium > 75%) after main branch (MB) BRS implantation. Clinical outcomes including cardiac death, follow‐up myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), and definite scaffold thrombosis (ST) were investigated. Results The majority of target lesions were in the left anterior descending artery (73.0%) and the rate of true bifurcation lesions was 42.6%. SB strut dilation was performed in only 20% of lesions ( n = 23), and intravascular imaging was used in most cases (90.4%). The rates of TLR per lesion at 1‐year was 3.1% in MB, and 0% in SB. In all patients, the cumulative rate of cardiac death was 1.1% at 1‐year, follow‐up MI 2.2%, TVR 3.5%, and definite ST 1.0%. Conclusion Clinical outcomes were acceptable in bifurcation lesions treated with single crossover BRS implantation without routine SB strut dilation. © 2016 Wiley Periodicals, Inc.